共 54 条
[1]
Rader RA., Redefining biopharmaceutical, Nat Biotechnol, 26, 7, pp. 743-751, (2008)
[2]
Mehta HM, Malandra M, Corey SJ., G-CSF and GM-CSF in Neutropenia, J Immunol, 195, 4, pp. 1341-1349, (2015)
[3]
Wittman B, Horan J, Lyman GH., Prophylactic colo-ny-stimulating factors in children receiving myelo-suppressive chemotherapy: a meta-analysis of randomized controlled trials, Cancer Treat Rev, 32, 4, pp. 289-303, (2006)
[4]
Yang B-B, Kido A., Pharmacokinetics and pharmaco-dynamics of pegfilgrastim, Clin Pharmacokinet, 50, 5, pp. 295-306, (2011)
[5]
Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G., Filgrastim (r-metHuG-CSF): the first 10 years, (1996)
[6]
Sivakumaran M, Vasconcelos ZF, Diamond HR, Tabak DG, Barcinski MA, Bonomo A, Et al., Fil-grastim prevents severe neutropenia and reduces in-fective morbidity in patients with advanced HIV in-fection: results of a randomized, multicenter, controlled trial. G-CSF 930101 study group, Blood, 97, 1, pp. 333-335, (2001)
[7]
Babalola CP, Nightingale CH, Nicolau DP., Adjunc-tive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts, J Antimi-crob Chemother, 53, 6, pp. 1098-1100, (2004)
[8]
Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME., Randomised pla-cebo-controlled trial of granulocyte-colony stimulat-ing factor in diabetic foot infection, Lancet, 350, 9081, pp. 855-859, (1997)
[9]
Vanz AL, Renard G, Palma MS, Chies JM, Dalmora SL, Basso LA, Et al., Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization, Microb Cell Fact, 7, 1, (2008)
[10]
Kesik-Brodacka M., Progress in biopharmaceutical development, Biotechnol Appl Biochem, 65, 3, pp. 306-322, (2018)